Today: 20 March 2026
Subscribe
Browse Category

TSX:AG 26 November 2025 - 14 February 2026

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 14.02.2026

First Majestic Silver shares rose 6.4% in a day and 13.6% this month, now up 85.53% over 90 days. The stock trades at CA$31.28, with some analysts valuing it as high as CA$120, while a discounted cash flow model puts fair value at CA$30.03. Debate continues over valuation and risks tied to production and cost controls after the Gatos acquisition.
14 February 2026
·
First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver (AG) Blasts to a 52‑Week High as Silver Hits Records – Can the Run Last?

First Majestic Silver shares hit a 52-week high of $16.30 on December 11, trading near $16.50 intraday, after silver prices reached all-time highs. The stock is up about 185–190% year-to-date, lifting market cap to $7.5–8.0 billion. Q3 2025 saw record silver production of 3.9 million ounces and EBITDA of $128.6 million. Net earnings reached $43 million, reversing a loss from last year.
11 December 2025
···
First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

First Majestic Silver shares traded near $15.40 on December 10, 2025, close to their 52-week high, after more than doubling year-to-date. Spot silver surged past $60 an ounce for the first time, driven by supply deficits and strong industrial demand. The company reported record production and earnings, and completed a $350 million convertible note offering. Market cap stands near $7.6 billion.
10 December 2025
···

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop